ERK-IN-3

CAS No. 2055597-12-9

ERK-IN-3( ASN007 free base )

Catalog No. M23920 CAS No. 2055597-12-9

ERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 71 In Stock
5MG 113 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ERK-IN-3
  • Note
    Research use only, not for human use.
  • Brief Description
    ERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
  • Description
    ERK-IN-3 is a potent and orally active inhibitor of ERK. It inhibits ERK1/2 with low single-digit nM IC50 values. It can be used for the research of cancers driven by RAS mutations.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ASN007 free base
  • Pathway
    MAPK/ERK Signaling
  • Target
    ERK
  • Recptor
    ERK1|ERK2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2055597-12-9
  • Formula Weight
    473.93
  • Molecular Formula
    C22H25ClFN7O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:250 mg/mL (527.50 mM; Need ultrasonic)
  • SMILES
    O=C(C1=CN(C2=NC(NC3CCOCC3)=NC=C2C)C=N1)N[C@@H](C4=CC(F)=CC(Cl)=C4)CN
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sanjeeva PR, et, al. Abstract B150: ASN007, a novel oral ERK inhibitor, shows robust antitumor activity in RAS mutant cancer models. Molecular Cancer Therapeutics. 2018 Jan; 17(1).
molnova catalog
related products
  • Mogrol

    Mogrol is a biometabolite of mogrosides. Mogrol acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.

  • Officinalisinin I

    Officinalisinin I can effectively reduce the blood glucose and protect nerve injuryin diabetic mice.

  • Muramyl dipeptide

    Muramyl dipeptide is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln.